We conclude from these results and literature review that absence of CK19 expression can be expected in around 4 % to 7 % of breast carcinomas with either a luminal or nontriple-negative phenotype (which can include the Her2 phenotype). The gene discussed is KRT19; the disease is breast carcinoma.